Gentamicin/vancomycin - Armis Biopharma/Dr Reddys Laboratories

Drug Profile

Gentamicin/vancomycin - Armis Biopharma/Dr Reddys Laboratories

Alternative Names: DFA-02; Vancomycin/gentamicin; Ximycin

Latest Information Update: 12 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dr Reddys Laboratories; Duke Clinical Research Institute
  • Class Aminoglycosides; Antibacterials; Glycopeptides; Peptide antibiotics; Small molecules
  • Mechanism of Action Cell wall inhibitors; Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Postoperative infections

Most Recent Events

  • 07 Feb 2018 Armis Biopharma has patent protection for gentamicin/vancomycin
  • 29 Jan 2018 Armis Biopharma plans a phase III registration trial for Postoperative infections (Surgical site infections) (Prevention) in first half of 2018
  • 29 Jan 2018 Gentamicin/vancomycin - Armis Biopharma/Dr Reddys Laboratories receives Qualified Infectious Disease Product status for Postoperative infections (Prevention) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top